Kornimate/medical-research-clean huggingface dataset:
the effect of laser therapy in the management of adhesive capsulitis: a randomized clinical trial

Conditions: Pain Disorder; Low Level Laser Therapy

Summary: in this study, it was aimed to compare the effects of low-level laser therapy (lllt) and high-intensity laser therapy (hilt) on shoulder joint range of motion, level of pain and functional status in patients with adhesive capsulitis

this study will be designed as a randomized, prospective, single-blind clinical trial with a 3-week follow-up. a total of 50 patients who applied to our hospital with the complaint of shoulder pain will be evaluated for inclusion in the study. patients will be randomized into two groups as high-intensity laser (hilt) + stretching exercise group and low-level laser (lllt) + stretching exercise group.

Eligibility criteria:
inclusion criteria: 1. patients aged between 25-65 years 2. patients clinically diagnosed with adhesive capsulitis, characterized by limitation of passive external rotation of the affected shoulder to less than 50% of the contralateral shoulder and normal radiographic finding of the affected shoulder 3. patients with severe pain and shoulder limitation for at least 3 months 4. patients who are literate and able to understand verbal instructions in our language. exclusion criteria: 1. calcific tendinopathy, glenohumeral osteoarthritis, fracture, shoulder surgery, shoulder trauma, history of malignancy and infection, history of inflammatory rheumatic diseases 2. history of bilateral simultaneous adhesive capsulitis 3. recent history of lung, breast, or bypass surgery/radiotherapy 4. history of corticosteroid injection to the same shoulder in the last 1 year 5. history of cervical radiculopathy/brachial plexus lesion 6. neuromuscular disease history 7. history of physical therapy program for the same shoulder in the last 6 months.

Keywords: adhesive capsulitis pain high-intensity laser therapy low-level laser therapy pain
clinical outcome of extended-depth-of-focus intraocualr lens (sav) implantation

Conditions: Presbyopia

Summary: clinical outcome of extended-depth-of-focus intraocular lens (sav) implantation

in this study, we are trying to evaluate the clinical outcome of extended-depth-of-focus intraocular lens (sav).

Eligibility criteria:
inclusion criteria: 1. adult at the age of 21 or older at the time of the pre-operative examination and willing to have surgery on their 2nd eye within 7-28 days of their 1st eye 2. age-related cataract 3. a patient with preoperative corneal astigmatism from iol master less than 1 diopters 4. a patient want presbyopia correction at the same time as cataract surgery 5. a patient has the visual potential of 20/25 or better in each eye after cataract removal and iol implantation 6. written informed consent to surgery and participation in the study exclusion criteria: 1. those with other diseases that can affect capsule stability such as pseudoexoliation syndrome, glaucoma, traumatic cataract 2. pregnant woman and lactating woman 3. a patient with history of ocular trauma or ocular surgery (intraocular surgery, refractive surgery, ocular surface surgery) in either eye 4. a patient with evidence of keratoconus or significant irregular astigmatism on pre-operative topography in either eye 5. if expectations for presbyopia correction are too high 6. those who are not able to read and understand the informed consent (illiterate or foreigners)

Keywords: depth and focus
the gi binder: a psychoeducational intervention for gastrointestinal cancer patients

Conditions: Gastro Intestinal Cancer

Summary: this research study is evaluating the use of a binder of educational materials with nurse teaching to prepare patients for chemotherapy

this research study is being done to investigate the feasibility of providing a binder of educational materials with nurse-led instruction in preparing pancreatic and colorectal cancer patients at dana farber for chemotherapy. the investigators want to evaluate whether the binder is helpful and usable for patients; and its effect on knowledge.

Eligibility criteria:
inclusion criteria: * able to read, write, and converse in english. * 18 years or older * scheduled for a new chemotherapy start (intravenous) to treat adenocarcinoma of the pancreas or colorectal cancer exclusion criteria: * enrolled in a clinical trial for chemotherapy * major psychological diagnoses that would limit participation

Keywords: gastro intestinal cancer
sms-based mobile health intervention for nutritional status and treatment outcome among tb patients

Conditions: Tuberculosis; Undernutrition

Summary: ethiopia is one of the high burden tuberculosis countries and tuberculosis is still the leading cause of mortality due to communicable diseases in the country. nutritional status is one of the predictors of tb treatment outcomes. thus, the current practices need integration of nutritional intervention in the dot using mobile health intervention. however, to investigator's knowledge, there is no sufficient evidence on the effect sms text messaging mobile health intervention on nutritional status and tb treatment outcomes in ethiopia.

to ensure the quality of sms intervention, nutritional related sms text message will be developed systematically through reviewing literature, systematic reviews and guidelines and appropriate behavioral theories by involving experts and patients. automated sms will be sent from one computer database at the scheduled date and time. a validated questionnaire will be adapted and pre-tested to check for any error. adequate sample size is calculated for both arms with the ratio of 1:1 allocation. standardized anthropometric measurement, fanta household dietary diversity score and who tb treatment outcome classification will be used for assessing the outcome variables. the data collectors will be trained on the objective, screening of eligible participants, the procedure of data collection, and how to assure the quality and security of the data based on the protocol. continuous supervision will be employed throughout the data collection and intervention period. the data will be collected electronically and will be exported to stata for analysis. intention to treat analysis and regression analysis model will be employed.

Eligibility criteria:
inclusion criteria: * patient who is following their anti tb treatment for at most two weeks and below * patient who have their own mobile phone * patient who is able to read and understand national official language (amharic) exclusion criteria: * patient whose tb treatment regimen more than 6 months * patient who is pregnant and lactating mothers * patient who enrolled other interventional research

Keywords: tuberculosis nutrition treatment outcome sms
adherence to antimalarial drugs in sierra leone

Conditions: Malaria

Summary: the aim of this study is to address this gap in knowledge by measuring the level of patient adherence to co-formulated amodiaquine and artesunate (aq-as) compared to artemether-lumefantrine (al) under routine conditions in sierra leone and explore the key factors that influence adherence. this will be addressed through a mixed methods study that will provide not only a measurement of adherence acts and malaria test results, but will also provide contextual information in order to better understand factors that affect adherence. data will be collected through a series of interviews with health workers and parents/caregivers and through observations of patient-provider consultations. the first stage of the study begins with semi-structured interviews and observations of patients/caretakers' consultations with health workers and will look at how health workers diagnose and treat malaria. this will be followed by short exit interviews at the health facility with caregivers to assess patient satisfaction with services, as well as to test the consistency between the data obtained through structured observations and the exit interviews. follow-up surveys at the homes of patients will be used to measure and compare the adherence of participants to two different acts (aqas and al) formulations and potential factors that affect adherence. additionally, data will be collected using in-depth interviews to collect supplementary information in order to discover, in more detail, factors that may affect behavioral choices and/or attitudes with regard to adherence.


Eligibility criteria:
inclusion criteria: * patient is a child between 6 to 59 months * visiting health facility for treatment of fever * do not have signs of severe disease * are not being referred to another health facility * living within a defined distance from the health facility (\<8 km/ 5 miles) * have not taken part in the study already or are not part of a household that has already taken part in the study * responsible caretakers/parents provide additional informed consent exclusion criteria: -
inferior vena cavacollapsibility index in patients with acute kidney injury

Conditions: Acute Kidney Injury

Summary: this is an observational study that will examine the possibility of determining the type of acute kidney injury (aki) using bedside ultrasound machines.

the investigators hypothesize that different types of aki (pre-renal, renal, and post-renal) are associated with different inferior vena cava diameters and collapsibility index. the investigators will include subjects ages 18-89 years with aki (creatinine of 2mg/100ml or higher for less than 24 hours from baseline creatinine ≤1.2 or with unknown baseline creatinine). standard of care treatment will not be different for patients taking part in this study. participants will have bedside ultrasounds on days 0, 1, and 3, and baseline and follow-up data will be collected from medical records.

Eligibility criteria:
inclusion criteria: 1. creatinine of 1.7 mg/100ml or higher for less than 24 hours from baseline creatinine ≤1.2 or with unknown baseline creatinine 2. age range: 18-89 years 3. age range ≥ 18 exclusion criteria: 1. only chronic renal disease will exclude a patient from our study regardless of past medical history and medications they are taking. (for the purposes of this study, any patient with creatinine higher than 1.2 mg /100ml for more than 24 hours will be identified as having chronic renal disease.)

Keywords: inferior vena cava kidney injury ultrasound
prognostic value of soluble urokinase-type plasminogen activator receptor in valvular heart disease

Conditions: Severe Aortic Stenosis or Severe Aortic Regurgitation

Summary: this study investigates the association between level of supar and valvular heart disease in patients who have severe aortic stenosis or severe aortic regurgitation using commercially available suparnostic standard enzyme-linked immunosorbent assay (virogates, denmark)


Eligibility criteria:
inclusion criteria: * age ≥ 19 yrs * severe aortic stenosis or severe aortic regurgitation * agree to consent for self * can follow-up for the next 2 years exclusion criteria: * pre-existing acute kidney injury * pre-existing end stage kidney disease: estimated glomerular filtration rate (egfr) ≤15 ml/min/1.73m2 or receiving renal replacement therapy * on ecmo or iabp * life expectancy \< 12 months * pregnancy
third generation cognitive behavioural therapy vs treatment-as-usual for adhd

Conditions: Adhd

Summary: the investigators hypothesize that the mindfulness cognitive behavioral therapy program will lead to a reduction in attention deficit and hyperactivity disorder symptoms, anxiety and depression, and improve self-confidence, emotional control, social integration and school results.


Eligibility criteria:
inclusion criteria: * if deemed able, the patient must have given his/her informed and signed consent * the parents (or legal guardian) of minor patients must have given their informed and signed consent. * the patient and participating parents must be insured or beneficiary of a health insurance plan * the patient is equal to or greater than 7 years old and less than or equal to 15 years old * the patient presents with attention deficit and hyperactivity disorder with an adhdrs-pi score \> 27 * the patient is currently not under treatment - or - is treated with methylphenidate with a stable posology (not expected to vary in the near future) but remains symptomatic exclusion criteria: * the patient is participating in, or has participated in over the past three months, another trial or another study that may interfere with the results or conclusion of the present study * the patient is in an exclusion period determined by a previous study * the participating parent(s) is(are) under judicial protection, or is an adult under guardianship * it is impossible to correctly inform the patient or his/her parent or legal guardian * patients or parents refusing participation, signature of the signed consent or follow-up procedures * previously documented mental retardation (iq \< 70) or suspicion thereof by the investigator * the patient has already participated in cognitive behavioural therapy (individual or group) in the six months preceding inclusion * patients diagnosed with autism spectrum disorder, psychotic disorder or bipolar disorder * the family has participated in a parental guidance programme in the last 6 months. * the family has already participated in the present study
exploratory study to assess the biological activity of zd6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage iv)

Conditions: Carcinoma, Renal Cell; Kidney Neoplasms

Summary: the purpose of this study is to assess the biological activity of zd6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage iv).


Eligibility criteria:
inclusion criteria: * newly diagnosed metastatic renal cell carcinoma * suitable for nephrectomy exclusion criteria: * prior chemotherapy, biological therapy or radiation therapy for renal cell carcinoma or within the last 3 years for any other cancer * significant cardiac event within 3 months of entry * any history of coronary angioplasty or history of myocardial infarction

Keywords: kidney cancer metastatic newly diagnosed renal cell carcinoma
effectiveness of tni vs. bipap in chronic global insufficiency in copd patients

Conditions: COPD Chronic Obstructive Pulmonary Disease

Summary: the purpose of this trial ist to investigate the difference of the efficacy of two systems for breath support in patients with copd.

the trial consists of 12 weeks of therapy that is divided into two sections. in the first 6-week section patients receive treatment with either tni or bipap and in the second 6-week section treatment is changed. the starting therapy is allocated to the patients via randomisation and should be started directly after the baseline visit. the treatment and the follow-up period end with the second visit after the second treatment section and the patient decides which device he/she wants to use further.

Eligibility criteria:
inclusion criteria: * presence of copd with chronic respiratory global insufficiency * chronic day-hypercapnia with pco2 \>= 50 mmhg and typical symptoms of ventilatory insufficiency or patients with exacerbation (after abate of acute symptomatology) with documented hypercapnia \>= 50 mmhg on preliminary findings * age 18 or older * the patient or caretaker must be able to operate the device after a specific training * patient must be willing to use the nhf-/bipap-device for the whole trial period for at least 5 hours/day * patient must be able to answer the questionnaires * written informed consent is obtained exclusion criteria: * presence of acute respiratory insufficiency * exacerbation of type i or ii in the last 4 weeks * conservative therapy including long-term oxygen therapy according to gold update 2011 is not exhausted * previous treatment with niv (non-invasive ventilation) in the last 14 days * clinical instability or acute illness (e.g. acute myocardial infarction, tachycardial atrial fibrillation) * signs of cardial decompensation (e.g. edema in the lower limbs, pleural effusion) * other serious concomitant diseases, the assessment of eligibility is at the discretion of the investigator * contraindications for niv * anamnestic suspicion or proven obstructive sleep apnea (osa) * relevant systemic infections, assessment of eligibility is at the discretion of the investigator * bmi \> 30 * other additional pulmonary diseases of other genesis or diseases that affect breathing (e.g. mucoviscidosis, scoliosis, muscular diseases) * lack of compliance * participation in other interventional trials at the same time * pregnant or nursing women * fertile female patients without effective contraceptive measures during trial participation

Keywords: copd, nhf, bipap
prospective sampling in driver mutation pulmonary oncology patients on tyrosine kinase inhibitors (start-tki)

Conditions: Non Small Cell Lung Cancer; Liquid Biopsy; Tyrosine Kinase Inhibitor

Summary: the study is perfomed with adult patients with non-small cell lung cancer treated with tyrosine kinase inhibitor. the objective is to collect repeated samples of blood from patients (starting) on a tyrosine kinase inhibitor, for liquid mutation testing, and pharmacokinetic analysis.

this is an observational study in pulmonary oncology patients treated with tki. ideally before start of therapy, at week 4, 8 12, and then every 4-8 weeks (following the standard of care clinical pathways local guidelines) extra tubes of blood will be collected during blood withdrawal planned for standard-of-care. when a tki switch takes place, patients receive a new study number and the blood collection will be continued following standard-of-care. sampling will be performed during steady-state in working hours before next ingestion of tki (the regular morning dose will need to be postponed until after blood withdrawal). the moment of blood withdrawal after start of therapy and after last dosage of tki will be registered. at the time of progression the current standard of care is to perform a rebiopsy, to identify the resistance mechanism and determine the next appropriate systemic therapy for a patient. some mechanisms can only be determined on a biopsy specimen (e.g. transformation to sclc, met amplification fish). this study is observational and will not interfere with the current standard practice, therefore the treating physician is free to determine the indication for and possibility of a rebiopsy. however, when a biopsy is taken as standard of care, we will also draw an extra blood sample on the day of the biopsy (preferably during standard preprocedural coagulation status laboratory investigations) and use a portion of the biopsy for a fresh frozen specimen, as evolving molecular investigations (like rna analysis) often need fresh non-fixed material to obtain reliable results. four to five core biopsies will be obtained for further analysis. half of the obtained biopsy material will be stored in formalin according to local standard procedures, while the other half will be fresh frozen according to local standard procedures and stored for further analysis. when the treating physician needs to take additional tissue or liquid (e.g. pleural fluid, liquor) for investigations following standard-of-care protocols, we would like to perform additional molecular and/or pharmacokinetic analysis on the residual material when applicable.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * able to understand the written informed and able to give informed consent * locally advanced or metastatic nsclc with oncogenic driver mutation * treatment with tki according to standard of care exclusion criteria: * unable to draw blood for study purposes
physical activity behavioral intervention in obese endometrial cancer survivors

Conditions: Stage IA Uterine Corpus Cancer; Stage IB Uterine Corpus Cancer; Stage II Uterine Corpus Cancer; Stage IIIA Uterine Corpus Cancer; Stage IIIB Uterine Corpus Cancer; Stage IIIC Uterine Corpus Cancer; Stage IVA Uterine Corpus Cancer; Stage IVB Uterine Corpus Cancer

Summary: this randomized clinical trial studies a physical activity behavioral intervention in obese endometrial cancer survivors. learning about physical activity behavior while participating in a fitness class may help increase physical activity and improve the quality of life of obese endometrial cancer survivors.

primary objectives: i. to determine the effect of a 12-week behavior/exercise intervention on moderate-vigorous physical activity (\> 150 minutes) among ethnically diverse endometrial cancer survivors. secondary objectives: i. to determine the effects of a 12-week behavior/exercise intervention on body composition among ethnically diverse endometrial cancer survivors. tertiary objectives: i. to determine the effects of a 12-week behavior/exercise intervention for ethnically diverse endometrial cancer survivors on physical function and quality-of-life. ii. to determine the most important behavioral variables for predicting physical activity adherence. iii. to determine the most significant facilitators and barriers to adherence during the 12-week intervention. iv. to compare the thematic differences between high-adherence and low-adherence participants and qualitatively assess the strengths and weaknesses of the 12-week intervention. outline: participants are randomized to 1 of 2 groups group i: participants partake in 30 minutes of group discussions regarding physical activity behavior followed by 60 minutes of moderate-intensity exercise comprised of 5 minutes warm-up, 25 minutes cardiovascular training, 20 minutes of resistance training exercises using body weight and exercise band, and 10 minutes of cool-down and stretching once weekly for 12 weeks. participants also complete a brisk walk for 90 minutes per week outside of class for 12 weeks. group ii: participants receive a handout indicating the importance of physical activity and improved nutrition for health outcomes. after 12 weeks, patients are invited to participate in the physical behavior intervention as in group i. after completion of study, participants are followed up at 12 weeks.

Eligibility criteria:
inclusion criteria: * written informed consent form signed and dated by the subject * english and/or spanish speaking * history of endometrial cancer stage i-iv \> 6 months \< 5 years, not currently receiving cancer treatment * overweight (body mass index \[bmi\] \>= 30) * eastern cooperative oncology group performance status (ps) of 0 - 2 * medically capable of performing moderate intensity exercise exclusion criteria: * must not have engaged in a regular (\> 3x/week, physical activity program in the last 6 months) * medical contraindication to exercise